Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mustang Bio Inc    MBIO

MUSTANG BIO INC

(MBIO)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/12/2019 04/15/2019 04/16/2019 04/17/2019 04/18/2019 Date
3.06(c) 2.78(c) 2.81(c) 2.66(c) 5.64(c) Last
38 345 64 748 39 296 1 304 701 37 568 580 Volume
-4.97% -9.15% +1.08% -5.34% +112.03% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -43,2 M
Net income 2019 -43,1 M
Debt 2019 -
Yield 2019 -
Sales 2020 -
EBIT 2020 -49,7 M
Net income 2020 -49,3 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 0
Capi. / Sales2020 0
Capitalization 160 M
More Financials
Company
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies... 
More about the company
Latest news on MUSTANG BIO INC
04/18MUSTANG BIO : St. Jude Children's Research Hospital publishes results of Lentivi..
AQ
04/18MUSTANG BIO : St. Jude Childrens Research Hospital publishes results of Lentivir..
AQ
04/17St. Jude Children's Research Hospital publishes results of Lentiviral Gene Th..
GL
04/10MUSTANG BIO : to Present at the World Orphan Drug Congress USA 2019
AQ
04/09MUSTANG BIO : to Present at the World Orphan Drug Congress USA 2019
AQ
04/04MUSTANG BIO, INC. : Entry into a Material Definitive Agreement, Financial Statem..
AQ
04/01HORIZON TECHNOLOGY FINANCE : Mustang Bio Announces $20 Million Venture Debt Fina..
AQ
03/19MUSTANG BIO : Reports Full-Year 2018 Financial Results and Recent Corporate High..
AQ
03/18MUSTANG BIO, INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
03/18MUSTANG BIO : Management's Discussion and Analysis of the Results of Operations ..
AQ
More news
Analyst Recommendations on MUSTANG BIO INC
More recommendations
Sector news : Bio Therapeutic Drugs
04/16GILEAD SCIENCES : Insitro to Collaborate on Nonalcoholic Steatohepatitis
DJ
04/15PATRICK THOMAS : Novartis Files Application for Macular Degeneration Treatment
DJ
04/12GILEAD SCIENCES : Novo Nordisk Plan NASH Collaboration
DJ
04/08GSK wins U.S. nod for two-drug HIV combination
RE
04/08Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance
DJ
More sector news : Bio Therapeutic Drugs
Chart MUSTANG BIO INC
Duration : Period :
Mustang Bio Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MUSTANG BIO INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 18,0 $
Spread / Average Target 219%
EPS Revisions
Managers
NameTitle
Manuel Litchman President, Chief Executive Officer & Director
Michael Sean Weiss Chairman
Brian Achenbach Vice President-Finance & Controller
Sadik Kassim Chief Scientific Officer
Knut Niss Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
MUSTANG BIO INC91.84%160
GILEAD SCIENCES0.64%80 255
VERTEX PHARMACEUTICALS1.48%42 991
REGENERON PHARMACEUTICALS-10.75%35 789
GENMAB5.11%10 418
SAREPTA THERAPEUTICS INC6.88%8 594